Development and Production of Chikungunya vaccines

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Abstract

Production of candidate chikungunya vaccines for human clinical trials will be done in compliance with current Good Manufacturing Practices (cGMP) and released for use in human clinical trials. This will necessitate developing production methods based upon novel cell substrates and If these trials demonstrate safety and immunogenicity of this vaccine in human trials, further evaluation may take place in larger (Phase 2) trials which will necessitate production of the clinical trial materials (CTM) at large scale.